VINC Stock Overview
A clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vincerx Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.19 |
| 52 Week High | US$9.37 |
| 52 Week Low | US$0.18 |
| Beta | 1.18 |
| 1 Month Change | -26.52% |
| 3 Month Change | -71.68% |
| 1 Year Change | -83.56% |
| 3 Year Change | -98.10% |
| 5 Year Change | n/a |
| Change since IPO | -97.93% |
Recent News & Updates
Recent updates
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely
Aug 21
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Jul 18Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Mar 30Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Sep 22Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?
Jun 24Vincerx Pharma doses first patient in early-stage VIP152 cancer study
Jun 03Shareholder Returns
| VINC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.3% | 2.6% | 2.8% |
| 1Y | -83.6% | -3.3% | 24.6% |
Return vs Industry: VINC underperformed the US Biotechs industry which returned -3.3% over the past year.
Return vs Market: VINC underperformed the US Market which returned 24.6% over the past year.
Price Volatility
| VINC volatility | |
|---|---|
| VINC Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VINC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VINC's weekly volatility has decreased from 23% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 42 | Ahmed Hamdy | vincerx.com |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies.
Vincerx Pharma, Inc. Fundamentals Summary
| VINC fundamental statistics | |
|---|---|
| Market cap | US$6.17m |
| Earnings (TTM) | -US$27.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs VINC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VINC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.03m |
| Earnings | -US$27.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VINC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 22:43 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vincerx Pharma, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kalpit Patel | B. Riley Securities, Inc. |
| Michael King | H.C. Wainwright & Co. |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |